via Quietly on Jan. 13, Nextcure (NASDAQ: NXTC) filed a terse 8-K with the SEC stating that Eli Lilly (NYSE: LLY) was terminating a research and development pact forged in November 2018. Nextcure's stock righted itself after a brief sell-off the morning after the filing. article source